- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Lakewood-Amedex Biotherapeutics Inc.: Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers | 84 | PR Newswire | Leading clinician and surgeon to also serve as Scientific Advisor for Lakewood-Amedex Biotherapeutics' iDFU program
SARASOTA, Fla., June 25, 2026 /PRNewswire/ --... ► Artikel lesen | |
| 17.06. | Lakewood-Amedex Biotherapeutics kündigt Aktienzusammenlegung im Verhältnis 1:10 an | 1 | Investing.com Deutsch | ||
| 17.06. | Lakewood-Amedex Biotherapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| LAKEWOOD-AMEDEX BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.05. | Lakewood-Amedex receives patents in Australia, New Zealand | 2 | Investing.com | ||
| 22.05. | Lakewood-Amedex Biotherapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 18.05. | Lakewood-Amedex Shares Fall 20% Despite Positive Nu-3 Development Update | 12 | RTTNews | ||
| 12.05. | Lakewood-Amedex Biotherapeutics Inc.: Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3 | 183 | PR Newswire | Specialized CRO partnership supports Phase 2 program to advance Nu-3 toward potential registration pathway in large, underserved iDFU market
SARASOTA, Fla., May... ► Artikel lesen | |
| 01.05. | Lakewood-Amedex Biotherapeutics Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 01.05. | Lakewood-Amedex reports resistance data for diabetic ulcer drug | 2 | Investing.com | ||
| 28.04. | Lakewood-Amedex beruft CEO von Enveric in den Verwaltungsrat | 3 | Investing.com Deutsch | ||
| 28.04. | Lakewood-Amedex appoints Enveric CEO to board of directors | 3 | Investing.com | ||
| 24.04. | Lakewood-Amedex-Aktie legt bei NASDAQ-Debüt um 20 % zu | 5 | Investing.com Deutsch | ||
| 23.04. | Lakewood-Amedex Biotherapeutics Inc.: Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT" | 341 | PR Newswire | SARASOTA, Fla., April 23, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT), a clinical-stage biotechnology company advancing a novel class... ► Artikel lesen | |
| 17.04. | Lakewood-Amedex Biotherapeutics Inc. - 8-A12B, Registration of securities | - | SEC Filings | ||
| 01.04. | Lakewood-Amedex Biotherapeutics Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 13.02. | Lakewood-Amedex Biotherapeutics Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 05.02. | Lakewood-Amedex Biotherapeutics Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 09.01. | Lakewood-Amedex Biotherapeutics Inc. - S-1, General form for registration of securities | - | SEC Filings |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 0,969 | +0,68 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| INFLARX | 1,687 | -0,24 % | InflaRx NV im Höhenflug: Was hinter dem Kursanstieg wirklich steckt - Was ich konkret unternommen habe! | ||
| INTELLIA THERAPEUTICS | 14,120 | -3,42 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| IBIO | 1,443 | -1,30 % | iBio, Inc.: iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity | IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition First-in-human study of IBIO-600 to evaluate safety,... ► Artikel lesen | |
| IMMUNITYBIO | 7,590 | 0,00 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 8,200 | -1,97 % | Immatics N.V. - S-8, Securities to be offered to employees in employee benefit plans | ||
| MANNKIND | 3,577 | 0,00 % | MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza in Youth with Newly-Diagnosed T1D | Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE... ► Artikel lesen | |
| IMMUNIC | 13,115 | -1,83 % | EQS-News: Immunic AG: Immunic to Participate in Investor, Industry and Scientific Conferences in June | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor, Industry and Scientific Conferences in June
10.06.2026 / 12:30 CET/CEST
The issuer is... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 3,740 | +0,54 % | Iovance Biotherapeutics, Inc.: Iovance's Amtagvi (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia | First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE... ► Artikel lesen | |
| GUARDANT HEALTH | 129,74 | -1,08 % | Bernstein upgrades Guardant Health stock rating on FDA approval impact | ||
| MOLECULIN BIOTECH | 3,400 | +3,98 % | Moleculin Biotech, Inc.: Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial | Early blinded results show 40% composite complete remission rate across difficult-to-treat AML patient population in MIRACLE Trial First interim unblinding expected in June 2026 following 45 subject... ► Artikel lesen | |
| INSMED | 91,50 | +0,73 % | EQS-News: EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis | EQS-News: EMBARC
/ Key word(s): Study/Letter of Intent
EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification... ► Artikel lesen | |
| GENPREX | 0,504 | +1,82 % | Genprex, Inc.: Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer | Patent Covers Acclaim-3 Clinical Trials Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq®
AUSTIN, Texas, June 22, 2026 /PRNewswire/ -- Genprex, Inc.... ► Artikel lesen | |
| MACROGENICS | 4,320 | +2,37 % | MacroGenics, Inc.: MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD Approval | ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment... ► Artikel lesen | |
| KARYOPHARM | 8,600 | -3,91 % | Karyopharm Therapeutics Inc.: Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment | - Completed Enrollment of Phase 3 XPORT-EC-042 Trial in Endometrial Cancer; Topline Data Expected Mid-2026 -
- Phase 3 SENTRY Results Selected for Late-Breaking... ► Artikel lesen |
Das Unternehmen LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,50 % bei einem Aktienkurs von 3,950 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.